image
Arcadia Biosciences, Inc. RKDA
Basic Materials - Agricultural Inputs - NASDAQ - US
Watchlist
$ 4.955
3.68 %
$ 6.77 M
Market Cap
-8.4
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one RKDA stock under the worst case scenario is HIDDEN Compared to the current market price of 4.96 USD, Arcadia Biosciences, Inc. is HIDDEN

RKDA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one RKDA stock under the base case scenario is HIDDEN Compared to the current market price of 4.96 USD, Arcadia Biosciences, Inc. is HIDDEN

RKDA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one RKDA stock under the best case scenario is HIDDEN Compared to the current market price of 4.96 USD, Arcadia Biosciences, Inc. is HIDDEN

RKDA Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart RKDA

image
1M 22%
6M -27%
1Y 56.0%
3Y -788%
5Y -3274%
All
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.515 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
5.04 M REVENUE
-5.35%
Growth Rates
1Year -5.35%
3Years -9.38%
5Years 33.97%
7Years 3.28%
10Years -3.20%
-3.65 M OPERATING INCOME
73.69%
Growth Rates
1Year 73.69%
3Years 53.17%
5Years 29.11%
7Years 17.74%
10Years 13.27%
-7.04 M NET INCOME
49.68%
Growth Rates
1Year 49.68%
3Years 24.16%
5Years 24.60%
7Years 10.84%
10Years 9.13%
-9.63 M OPERATING CASH FLOW
37.05%
Growth Rates
1Year 37.05%
3Years 28.07%
5Years 10.96%
7Years 5.18%
10Years 4.20%
7.34 M INVESTING CASH FLOW
269.01%
Growth Rates
1Year 269.01%
3Years -23.82%
5Years 23.54%
7Years -23.34%
10Years 20.80%
9 K FINANCING CASH FLOW
-99.84%
Growth Rates
1Year -99.84%
3Years -92.57%
5Years -78.99%
7Years 10.41%
10Years -55.58%
1.2 M REVENUE
-1.32%
Growth Rates
1Year -5.35%
3Years -9.38%
5Years 33.97%
7Years 3.28%
10Years -3.20%
530 K OPERATING INCOME
123.26%
Growth Rates
1Year 73.69%
3Years 53.17%
5Years 29.11%
7Years 17.74%
10Years 13.27%
2.6 M NET INCOME
164.38%
Growth Rates
1Year 49.68%
3Years 24.16%
5Years 24.60%
7Years 10.84%
10Years 9.13%
-1.59 M OPERATING CASH FLOW
28.11%
Growth Rates
1Year 37.05%
3Years 28.07%
5Years 10.96%
7Years 5.18%
10Years 4.20%
500 K INVESTING CASH FLOW
-80.12%
Growth Rates
1Year 269.01%
3Years -23.82%
5Years 23.54%
7Years -23.34%
10Years 20.80%
5 K FINANCING CASH FLOW
0.00%
Growth Rates
1Year -99.84%
3Years -92.57%
5Years -78.99%
7Years 10.41%
10Years -55.58%
Balance Sheet Arcadia Biosciences, Inc.
image
Current Assets 9.24 M
Cash & Short-Term Investments 4.24 M
Receivables 3.07 M
Other Current Assets 1.93 M
Non-Current Assets 4.28 M
Long-Term Investments 0
PP&E 178 K
Other Non-Current Assets 4.1 M
31.38 %22.70 %14.29 %30.31 %Total Assets$13.5m
Current Liabilities 2.56 M
Accounts Payable 703 K
Short-Term Debt 155 K
Other Current Liabilities 1.7 M
Non-Current Liabilities 4.73 M
Long-Term Debt 0
Other Non-Current Liabilities 4.73 M
9.64 %23.38 %64.86 %Total Liabilities$7.3m
EFFICIENCY
Earnings Waterfall Arcadia Biosciences, Inc.
image
Revenue 5.04 M
Cost Of Revenue 2.96 M
Gross Profit 2.08 M
Operating Expenses 5.73 M
Operating Income -3.65 M
Other Expenses 3.39 M
Net Income -7.04 M
6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)5m(3m)2m(6m)(4m)(3m)(7m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
41.27% GROSS MARGIN
41.27%
Averages
1Year 41.27%
3Years 26.97%
5Years 17.55%
7Years 23.84%
10Years 41.53%
-72.31% OPERATING MARGIN
-72.31%
Averages
1Year -72.31%
3Years -175.78%
5Years -264.01%
7Years -602.26%
10Years -544.29%
-139.50% NET MARGIN
-139.50%
Averages
1Year -139.50%
3Years -186.21%
5Years -174.32%
7Years -608.89%
10Years -559.96%
-113.10% ROE
-113.10%
Averages
1Year -113.10%
3Years -98.73%
5Years -73.96%
7Years -121.39%
10Years -117.90%
-52.07% ROA
-52.07%
Averages
1Year -52.07%
3Years -59.00%
5Years -45.29%
7Years -53.03%
10Years -52.49%
-32.90% ROIC
-32.90%
Averages
1Year -32.90%
3Years -62.44%
5Years -64.49%
7Years -67.92%
10Years -64.23%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Arcadia Biosciences, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -7.04 M
Depreciation & Amortization 113 K
Capital Expenditures -16 K
Stock-Based Compensation 512 K
Change in Working Capital -596 K
Others -2.3 M
Free Cash Flow -9.64 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Arcadia Biosciences, Inc.
image
RKDA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Arcadia Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
3.49 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
2.88 K USD 2
9-12 MONTHS
7. News
Arcadia Biosciences, Inc. (RKDA) Q1 2025 Earnings Call Transcript Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q1 2025 Earnings Conference Call May 8, 2025 2:00 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President and Chief Executive Officer Conference Call Participants Ben Klee - Lake Street Operator Hello, and welcome to Arcadia Biosciences First Quarter 2025 Financial Results and Business Highlights Conference Call. seekingalpha.com - 1 month ago
Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights -- Revenues increase 22% year over year driven by 90% growth in Zola ® -- -- Arcadia sells patents for $750K and eliminates $1M in liabilities -- -- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. globenewswire.com - 1 month ago
Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call Arcadia Biosciences, Inc.® (Nasdaq: RKDA) will release its financial and business results for the first quarter of 2025 on May 8, 2025 at 2:00 p.m. ET. globenewswire.com - 1 month ago
Arcadia Biosciences, Inc (RKDA) Q4 2024 Earnings Call Transcript Arcadia Biosciences, Inc (NASDAQ:RKDA ) Q4 2024 Results Conference Call March 20, 2025 4:30 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Operator Good afternoon, and welcome to Arcadia Biosciences Fourth Quarter and Full Year 2024 Financial Results and Business Highlights Conference Call. seekingalpha.com - 2 months ago
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024. “We are extremely pleased with the progress we made in 2024, particularly in the second half of the year following the sale of our GoodWheat™ assets,” said T.J. Schaefer, president and CEO. “Our focus on Zola® coconut water led to 80 percent revenue grow. businesswire.com - 2 months ago
Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2024 Financial Results and Business Highlights Conference Call DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the fourth quarter and full year of 2024 after market close on March 20, 2025. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss fourth-quarter and year-end results and key strategic achievements. Interested participa. businesswire.com - 3 months ago
RKDA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arcadia Biosciences, Inc. is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Arcadia Biosciences, Inc. (NASDAQ: RKDA) and Roosevelt Resources LP is fair to Arcadia shareholders. Upon closing of the proposed transaction, Arcadia shareholders are expected to own approximately 10% of the combined company. Halper Sadeh encourages Arcadia shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212. businesswire.com - 3 months ago
ARCADIA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Arcadia Biosciences, Inc. - RKDA NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Arcadia Biosciences, Inc. (NasdaqCM: RKDA) and Roosevelt Resources LP. Pursuant to the terms of the agreement, upon completion of the Merger, Arcadia stockholders are expected to own approximately 10% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are a. businesswire.com - 6 months ago
Arcadia Biosciences to Merge With Roosevelt, Shares Surge 105% RKDA inks deal with Roosevelt to become a new entity, Roosevelt Resources, with Roosevelt as the majority shareholder. zacks.com - 6 months ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Arcadia Biosciences, Inc. - RKDA NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Arcadia Biosciences, Inc. (NASDAQ: RKDA ), relating to the proposed merger with Roosevelt Resources LP. prnewswire.com - 6 months ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Arcadia Biosciences, Inc. NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Arcadia Biosciences, Inc. (NASDAQ: RKDA) and its board of directors concerning the proposed acquisition of the company by Roosevelt Resources LP. Arcadia stockholders will own approximately 10% of the combined company. prnewswire.com - 6 months ago
Shareholder Alert: Ademi LLP investigates whether Arcadia Biosciences, Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Arcadia (NASDAQ: RKDA) for possible breaches of fiduciary duty and other violations of law in its transaction with Roosevelt Resources. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Following the closing of the transaction, the current equity owners of Roosevelt Resources and the Arcadia shareholders. businesswire.com - 6 months ago
8. Profile Summary

Arcadia Biosciences, Inc. RKDA

image
COUNTRY US
INDUSTRY Agricultural Inputs
MARKET CAP $ 6.77 M
Dividend Yield 0.00%
Description Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
Contact 202 Cousteau Place, Davis, CA, 95618 https://www.arcadiabio.com
IPO Date May 15, 2015
Employees 9
Officers Mr. Thomas J. Schaefer C.F.A. Chief Executive Officer, President & Director Mr. Mark Kawakami Chief Financial Officer